Truist Financial upgraded shares of Pacira BioSciences (NASDAQ:PCRX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage currently has $25.00 price target on the stock, up from their prior price target of $8.00.
Several other research analysts have also recently issued reports on PCRX. Barclays decreased their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $26.20.
Check Out Our Latest Stock Analysis on PCRX
Pacira BioSciences Stock Performance
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its stake in Pacira BioSciences by 4.2% during the fourth quarter. Principal Financial Group Inc. now owns 257,733 shares of the company’s stock worth $4,856,000 after buying an additional 10,306 shares during the last quarter. Empowered Funds LLC grew its position in Pacira BioSciences by 5.1% during the 4th quarter. Empowered Funds LLC now owns 229,485 shares of the company’s stock worth $4,323,000 after acquiring an additional 11,149 shares during the last quarter. Caitlin John LLC increased its holdings in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. Finally, Gagnon Securities LLC boosted its stake in Pacira BioSciences by 4.8% in the fourth quarter. Gagnon Securities LLC now owns 321,743 shares of the company’s stock worth $6,062,000 after purchasing an additional 14,800 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.
Pacira BioSciences Company Profile
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Featured Stories
- Five stocks we like better than Pacira BioSciences
- What is the Dow Jones Industrial Average (DJIA)?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Profit From Growth Investing
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.